Jarrod Washburn isn't going to pitch anywhere this year

5 Comments

As the season goes on and teams get more desperate, the prospect of signing Jarrod Washburn to shore up the shaky rotation becomes less and less laughable.  But according to Jon Paul Morosi, don’t count on J-Wash (like that? I just came up with it!) coming to your hometown nine in 2010:

When asked by FOXSports.com if he still plans to pitch this year, he
said via e-mail Thursday: “Never say never, but I am very happy at home
with my family.”

Washburn was 9-9 with a 3.78 ERA last
season, but he posted a 7.33 ERA after being traded to Detroit. Between the second-half swoon, the apparent domestic bliss, and the almost complete lack of interest in him on the part of any team, he’s kind of like the pitching version of Jermaine Dye.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
0 Comments

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.